[go: up one dir, main page]

MA34106B1 - Combinaison de composés organiques - Google Patents

Combinaison de composés organiques

Info

Publication number
MA34106B1
MA34106B1 MA35274A MA35274A MA34106B1 MA 34106 B1 MA34106 B1 MA 34106B1 MA 35274 A MA35274 A MA 35274A MA 35274 A MA35274 A MA 35274A MA 34106 B1 MA34106 B1 MA 34106B1
Authority
MA
Morocco
Prior art keywords
combination
organic compounds
pharmaceutical combination
benzimidazol
methylpiperazin
Prior art date
Application number
MA35274A
Other languages
Arabic (ar)
English (en)
Inventor
Diana Graus-Porta
Michael Shi
Dean Brent Evans
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44009923&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA34106(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA34106B1 publication Critical patent/MA34106B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

L'invention concerne une combinaison pharmaceutique comprenant de la 4-amino-5-fluoro-3-[6-(4-méthylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one et au moins un inhibiteur de mtor, et la combinaison pharmaceutique destinée à être utilisée dans le traitement ou la prévention d'une maladie proliférative.
MA35274A 2010-04-16 2011-04-14 Combinaison de composés organiques MA34106B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32501810P 2010-04-16 2010-04-16
PCT/EP2011/055908 WO2011128405A1 (fr) 2010-04-16 2011-04-14 Combinaison de composés organiques

Publications (1)

Publication Number Publication Date
MA34106B1 true MA34106B1 (fr) 2013-03-05

Family

ID=44009923

Family Applications (1)

Application Number Title Priority Date Filing Date
MA35274A MA34106B1 (fr) 2010-04-16 2011-04-14 Combinaison de composés organiques

Country Status (19)

Country Link
US (1) US20130035343A1 (fr)
EP (1) EP2558082A1 (fr)
JP (1) JP2013525292A (fr)
KR (1) KR20130092412A (fr)
CN (1) CN102834094B (fr)
AU (1) AU2011240001B2 (fr)
BR (1) BR112012026285A2 (fr)
CA (1) CA2795089A1 (fr)
CL (1) CL2012002858A1 (fr)
IL (1) IL222313A0 (fr)
MA (1) MA34106B1 (fr)
MX (1) MX2012012058A (fr)
NZ (1) NZ602807A (fr)
PH (1) PH12012501977A1 (fr)
RU (1) RU2012148706A (fr)
SG (1) SG184311A1 (fr)
TN (1) TN2012000477A1 (fr)
WO (1) WO2011128405A1 (fr)
ZA (1) ZA201207234B (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR081776A1 (es) 2010-06-30 2012-10-17 Novartis Ag Composiciones farmaceuticas que comprenden monohidrato de lactato de 4-amino-5-fluoro-3-[6-(4-metil-piperazin-1-il)-1h-bencimidazol-2-il]-1h-quinolin-2-ona, proceso para la produccion de la composicion
US20150182525A1 (en) * 2011-05-19 2015-07-02 Novartis Ag 4-Amino-5-Fluoro-3-[6-(4-Methylpiperazin-1-YL)-1H-Benzimidazol-2-YL]-1H-Quinolin-2-one for use in the Treatment of Adenoid Cystic Carcinoma
GB201217890D0 (en) * 2012-10-05 2012-11-21 Virttu Biolog Ltd Treatment of cancer
WO2014160328A1 (fr) 2013-03-13 2014-10-02 The Board Of Regents Of The University Of Texas System Inhibiteurs de mtor pour la prévention de la croissance de polypes intestinaux
US9814703B2 (en) 2013-11-14 2017-11-14 The Board Of Trustees Of The Leland Stanford Junior University Methods for treating cancer by activation of BMP signaling
ES2900426T3 (es) 2013-12-31 2022-03-16 Rapamycin Holdings Llc Preparaciones orales y uso de nanopartículas de rapamicina

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT98990A (pt) 1990-09-19 1992-08-31 American Home Prod Processo para a preparacao de esteres de acidos carboxilicos de rapamicina
US5120842A (en) 1991-04-01 1992-06-09 American Home Products Corporation Silyl ethers of rapamycin
US5100883A (en) 1991-04-08 1992-03-31 American Home Products Corporation Fluorinated esters of rapamycin
US5118678A (en) 1991-04-17 1992-06-02 American Home Products Corporation Carbamates of rapamycin
US5118677A (en) 1991-05-20 1992-06-02 American Home Products Corporation Amide esters of rapamycin
US5151413A (en) 1991-11-06 1992-09-29 American Home Products Corporation Rapamycin acetals as immunosuppressant and antifungal agents
GB9125660D0 (en) 1991-12-03 1992-01-29 Smithkline Beecham Plc Novel compound
ZA935111B (en) 1992-07-17 1994-02-04 Smithkline Beecham Corp Rapamycin derivatives
ZA935112B (en) 1992-07-17 1994-02-08 Smithkline Beecham Corp Rapamycin derivatives
US5256790A (en) 1992-08-13 1993-10-26 American Home Products Corporation 27-hydroxyrapamycin and derivatives thereof
GB9221220D0 (en) 1992-10-09 1992-11-25 Sandoz Ag Organic componds
US5258389A (en) 1992-11-09 1993-11-02 Merck & Co., Inc. O-aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivatives
EP0729471A1 (fr) 1993-11-19 1996-09-04 Abbott Laboratories Analogues semi-synthetiques de rapamycine (macrolides) utilises comme immunomodulateurs
PL314238A1 (en) 1993-12-17 1996-09-02 Sandoz Ltd Rapamycin derivatives
CA2219659C (fr) 1995-06-09 2008-03-18 Novartis Ag Derives de rapamycine
EP0937082A2 (fr) 1996-07-12 1999-08-25 Ariad Pharmaceuticals, Inc. Elements et procedes pour traiter ou prevenir les mycoses pathog nes
CA2383451A1 (fr) 1999-08-24 2001-03-01 Ariad Gene Therapeutics, Inc. Analogues d'epirapamycine-28
AP1666A (en) 2000-09-11 2006-09-29 Chiron Corp Quinolinone derivatives as tyrosine kinase inhibitors.
CA2496164C (fr) 2002-08-23 2010-11-09 Chiron Corporation Quinolinones de benzimidazole et leurs utilisations
EP1682529A4 (fr) * 2003-11-07 2010-06-30 Novartis Vaccines & Diagnostic Methodes de synthese de composes de quinolinone
WO2005051432A1 (fr) * 2003-11-14 2005-06-09 Genvec, Inc. Regime therapeutique pour le traitement du cancer
EP1885187B1 (fr) * 2005-05-13 2013-09-25 Novartis AG Procedes pour traiter un cancer pharmacoresistant
EP1904480A2 (fr) 2005-05-23 2008-04-02 Novartis Pharma AG Formes cristalline et autres de sels d'acide lactique 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one
JPWO2008108386A1 (ja) * 2007-03-05 2010-06-17 協和発酵キリン株式会社 医薬組成物
AR070924A1 (es) 2008-03-19 2010-05-12 Novartis Ag Formas cristalinas y dos formas solvatadas de sales del acido lactico de 4- amino -5- fluoro-3-(5-(4-metilpiperazin-1-il ) -1h- bencimidazol-2-il) quinolin -2-(1h) - ona

Also Published As

Publication number Publication date
CN102834094B (zh) 2015-05-06
AU2011240001A1 (en) 2012-11-08
CA2795089A1 (fr) 2011-10-20
AU2011240001B2 (en) 2014-05-08
WO2011128405A1 (fr) 2011-10-20
BR112012026285A2 (pt) 2016-07-12
TN2012000477A1 (en) 2014-04-01
CL2012002858A1 (es) 2013-01-25
PH12012501977A1 (en) 2013-01-07
ZA201207234B (en) 2013-05-29
US20130035343A1 (en) 2013-02-07
KR20130092412A (ko) 2013-08-20
EP2558082A1 (fr) 2013-02-20
IL222313A0 (en) 2012-12-31
NZ602807A (en) 2014-02-28
RU2012148706A (ru) 2014-05-27
CN102834094A (zh) 2012-12-19
SG184311A1 (en) 2012-11-29
MX2012012058A (es) 2012-11-22
JP2013525292A (ja) 2013-06-20

Similar Documents

Publication Publication Date Title
MA39726A (fr) Compositions pharmaceutiques de composés thérapeutiquement actifs
MA40290A1 (fr) Agents immunorégulateurs
MA39725B1 (fr) Compositions pharmaceutiques de composés thérapeutiquement actifs
MA34106B1 (fr) Combinaison de composés organiques
MA34387B1 (fr) Compositions pharmaceutiques comprenant du lactate de 4-amino-5-fluoro-3-[6-(4-méthylpipérazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinoline-2-one monohydraté
MA41932B1 (fr) Méthodes de traitement ou de prévention de migraines
MA37829A1 (fr) Combinaisons pharmaceutiques comprenant un inhibiteur de b-raf, un inhibiteur d'egfr et facultativement un inhibiteur de pi3k alpha
MA35458B1 (fr) Variants du facteur de croissance des fibroblastes 21
ATE445624T1 (de) Verbindungen und zusammensetzungen als ppar- modulatoren
MA47217A (fr) Composés de n-((hét)arylméthyl)hétéroaryle-carboxamides en tant qu'inhibiteurs de la kallicréine plasmatique
MA38576B2 (fr) Formulations de colchicine à libération prolongée et procédés d'utilisation de ces dernières
MA34765B1 (fr) Antagonistes des récepteurs de l'acide lysophosphatidique et utilisations de ceux-ci
EP2868667A4 (fr) Agent thérapeutique à base d'anticorps anti-bmp9 en tant que principe actif, pour le traitement de l'anémie, notamment une anémie rénale et une anémie liée à un cancer
MA34449B1 (fr) Formulation de poudre seche comprenant un inhibiteur de phosphodiesterase
MA32230B1 (fr) Formes cristallines et deux formes solvatées de lactates de 4-amino-5-fluoro -3-[5-(4-méthylpipérazin-1-yl)-1h-benzimidazol-2-yl]quinolin-2(1h)-one
MA33295B1 (fr) Nouvelle formulation de diclofénac
MX2016016139A (es) Inhibidor del sistema complemento de ornithodoros moubata para utilizarse en el tratamiento de enfermedades mediadas por el sistema complemento en pacientes con polimorfismo de c5.
MA32458B1 (fr) Combinaison d'un antagoniste de c-met et d'un compose aminoheteroaryle pour le traitement d'un cancer
MA47356A1 (fr) Dérivés d'isochromène utiles en tant qu'inhibiteurs des phosphoinositide 3-kinases
MA38349A1 (fr) Œstra-1,3,5(10),16-tétraéno-3-carboxamide pour inhiber la 17-bêta-hydroxystéroïde déshydrogénase (akr1c3)
BR112012030641A2 (pt) métodos e composições para terapia farmacêutica oral
MA32841B1 (fr) Composés de cycloundeca depsipeptides et leur utilisation comme médicament
MA34952B1 (fr) Combinaisons comprenant du macitentan pour le traitement d'un glioblastome multiforme
MA39447B1 (fr) Pirlindole ou ses sels pharmaceutiquement acceptables pour une utilisation en médecine
EP3388446A4 (fr) Peptide amélioré inhibiteur de l'angiogenèse et composition pour prévenir et traiter une maladie associée à l'angiogenèse le comprenant en tant que principe actif